Stuttgart - Delayed Quote EUR

CytoDyn Inc (296.SG)

0.1400

+0.0050

(+3.70%)

At close: April 19 at 9:51 PM GMT+2

Currency in USD All numbers in thousands

Download

Breakdown

TTM

5/31/2023

5/31/2022

5/31/2021

5/31/2020

Total Revenue

--

--

266.0000

--

--

Cost of Revenue

--

20,633.0000

73,543.0000

--

--

Gross Profit

--

-20,633.0000

-73,277.0000

--

--

Operating Expense

15,204.0000

19,943.0000

72,127.0000

89,520.0000

74,647.0000

Operating Income

-15,204.0000

-40,576.0000

-145,404.0000

-89,520.0000

-74,647.0000

Net Non Operating Interest Income Expense

-29,481.0000

-30,498.0000

-61,563.0000

-61,241.0000

-33,247.0000

Other Income Expense

-7,005.0000

-8,750.0000

-3,853.0000

-25,704.0000

-32,042.0000

Pretax Income

-51,690.0000

-79,824.0000

-210,820.0000

-176,465.0000

-139,936.0000

Net Income Common Stockholders

-53,174.0000

-86,736.0000

-212,448.0000

-178,152.0000

-140,644.0000

Diluted NI Available to Com Stockholders

-53,174.0000

-86,736.0000

-212,448.0000

-178,152.0000

-140,644.0000

Basic EPS

-0.06

-0.10

-0.31

-0.30

-0.33

Diluted EPS

-0.06

-0.10

-0.31

-0.30

-0.33

Basic Average Shares

944,399.0000

836,528.0000

676,900.0000

587,590.0000

421,078.0000

Diluted Average Shares

944,399.0000

836,528.0000

676,900.0000

587,590.0000

421,078.0000

Total Operating Income as Reported

-15,204.0000

-40,576.0000

-145,404.0000

-104,596.0000

-74,647.0000

Total Expenses

15,204.0000

40,576.0000

145,670.0000

89,520.0000

74,647.0000

Net Income from Continuing & Discontinued Operation

-51,690.0000

-79,824.0000

-210,820.0000

-176,465.0000

-139,936.0000

Normalized Income

-44,685.0000

-71,074.0000

-206,967.0000

-150,761.0000

-107,894.0000

Interest Income

--

--

--

2.0000

5.3180

Interest Expense

6,045.0000

6,750.0000

15,066.0000

61,031.0000

32,412.0000

Net Interest Income

-29,481.0000

-30,498.0000

-61,563.0000

-61,241.0000

-33,247.0000

EBIT

-45,645.0000

-73,074.0000

-195,754.0000

-115,434.0000

-107,524.0000

EBITDA

-45,610.0000

-72,899.0000

-194,973.0000

-113,637.0000

-105,490.0000

Reconciled Cost of Revenue

--

20,633.0000

73,543.0000

--

--

Reconciled Depreciation

35.0000

175.0000

781.0000

1,797.0000

2,034.0000

Net Income from Continuing Operation Net Minority Interest

-51,690.0000

-79,824.0000

-210,820.0000

-176,465.0000

-139,936.0000

Total Unusual Items Excluding Goodwill

-7,005.0000

-8,750.0000

-3,853.0000

-25,704.0000

-32,042.0000

Total Unusual Items

-7,005.0000

-8,750.0000

-3,853.0000

-25,704.0000

-32,042.0000

Normalized EBITDA

-38,605.0000

-64,149.0000

-191,120.0000

-87,933.0000

-73,448.0000

5/31/2020 - 8/28/2017

Yahoo Finance Plus Essential access required. Unlock Access

NB11.F Vaxart, Inc.

0.7595

-5.42%

3G0.F Altimmune, Inc.

6.51

+0.09%

34LA.SG Alpine Immune Sciences Inc

59.50

0.00%

HGENQ Humanigen, Inc.

0.0000

0.00%

VIR Vir Biotechnology, Inc.

7.95

-0.13%

GNPX Genprex, Inc.

2.1300

-3.62%

FUSN Fusion Pharmaceuticals Inc.

21.26

+0.05%

GLSI Greenwich LifeSciences, Inc.

12.07

-6.36%

AIM AIM ImmunoTech Inc.

0.4650

-2.50%

ENZC Enzolytics, Inc.

0.0048

-1.23%